Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Cancer|March 26, 2008
Survival in patients with brain metastases from breast cancer: the importance of HER-2 statusApril F Eichler, Irene Kuter, Paula Ryan, et al.Plos One|February 8, 2014
Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patientsSteen Knudsen, Thomas Jensen, Anker Hansen, et al.Cancer|February 22, 2002
Immunologic quantitation of the carcinoma specific human carcinoma antigen in clinical samplesJohn F Codington, Svein Haavik, Najmosama Nikrui, et al.Clinical Breast Cancer|December 3, 2014
A good drug made better: the fulvestrant dose-response storyJohn F R Robertson, Justin Lindemann, Sally Garnett, et al.AJR. American Journal of Roentgenology|February 25, 2005
Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancerEren Yeh, Priscilla Slanetz, Daniel B Kopans, et al.Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 17, 2015
Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and TrastuzumabTimothy C Tan, Souhila Bouras, Heloisa Sawaya, et al.Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.Therapeutic Advances in Medical Oncology|January 16, 2023
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancerShannon McLaughlin, Erika Nakajima, Yael Bar, et al.Clinical Breast Cancer|September 11, 2014
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancerErica L Mayer, Adrienne B Gropper, Lyndsay Harris, et al.Pageof 3